Please log in to access this page.

Stalevo 150 side effects, by duration, gender and age (a phase IV clinical study of FDA data)

Summary:

Side effects are reported by people who take Stalevo 150 (carbidopa; entacapone; levodopa). Common side effects include abdominal pain among females and drug ineffective among males.

The phase IV clinical study is created by eHealthMe based on 70 reports from the FDA, and is updated regularly.

What is Stalevo 150?

Stalevo 150 has active ingredients of carbidopa; entacapone; levodopa. It is often used in parkinson's disease. eHealthMe is studying from 116 Stalevo 150 users. Check the latest studies of Stalevo 150.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

70 people who take Stalevo 150 and have side effects are studied.

Stalevo 150 side effects.

What are the common side effects of Stalevo 150, by gender? *:

female:

  1. Abdominal pain
  2. Coma (state of unconsciousness lasting more than six hours)
  3. Asthenia (weakness)
  4. Confusional state
  5. Drug effect decreased
  6. Drug ineffective
  7. Full blood count abnormal
  8. Hallucination, visual (seeing things that aren't there)
  9. Myalgia (muscle pain)
  10. Therapeutic response decreased (less preventive response)

male:

  1. Drug ineffective
  2. Asthenia (weakness)
  3. Aphasia (damage to the parts of the brain that control language)
  4. Avoidant personality disorder (shyness, sensitivity to rejection and avoidance of social situations)
  5. Back disorder
  6. Bezoar (mass found trapped in the gastrointestinal system)
  7. Cataract (clouding of the lens inside the eye)
  8. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  9. Colon cancer
  10. Constipation

What are the common side effects of Stalevo 150, by age (0-1 to 60+) *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Drug effect decreased

50-59:

  1. Drug ineffective

60+:

  1. Asthenia (weakness)
  2. Abdominal discomfort
  3. Agitation (state of anxiety or nervous excitement)
  4. Akinesia (loss of control of voluntary muscle movements)
  5. Coma (state of unconsciousness lasting more than six hours)
  6. Confusional state
  7. Drug ineffective
  8. Dyskinesia (abnormality or impairment of voluntary movement)
  9. Aggression
  10. Aphasia (damage to the parts of the brain that control language)

What are the common side effects of Stalevo 150, by the time people have been on the drug (< 1 month to 10+ years)? *:

< 1 month:

  1. Agitation (state of anxiety or nervous excitement)

1 - 6 months:

  1. Hypoaesthesia (reduced sense of touch or sensation)

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Dyskinesia (abnormality or impairment of voluntary movement)
  2. Fall
  3. Hyperphagia (an abnormal appetite for food)
  4. Aggression
  5. Aphasia (damage to the parts of the brain that control language)
  6. Avoidant personality disorder (shyness, sensitivity to rejection and avoidance of social situations)
  7. Back disorder
  8. Bezoar (mass found trapped in the gastrointestinal system)
  9. Cataract (clouding of the lens inside the eye)
  10. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)

* Approximation only. Some reports may have incomplete information.

Do you take Stalevo 150?

- Personalize this study to your gender and age
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.



How the study uses the data?

The study is based on carbidopa; entacapone; levodopa (the active ingredients of Stalevo 150) and Stalevo 150 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies are listed below in case you need more information:

Alternative drugs to, pros and cons of Stalevo 150:

All Stalevo 150 side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: